BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11559576)

  • 1. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.
    Mikolajczyk SD; Marker KM; Millar LS; Kumar A; Saedi MS; Payne JK; Evans CL; Gasior CL; Linton HJ; Carpenter P; Rittenhouse HG
    Cancer Res; 2001 Sep; 61(18):6958-63. PubMed ID: 11559576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.
    Mikolajczyk SD; Millar LS; Wang TJ; Rittenhouse HG; Marks LS; Song W; Wheeler TM; Slawin KM
    Cancer Res; 2000 Feb; 60(3):756-9. PubMed ID: 10676664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum.
    Mikolajczyk SD; Grauer LS; Millar LS; Hill TM; Kumar A; Rittenhouse HG; Wolfert RL; Saedi MS
    Urology; 1997 Nov; 50(5):710-4. PubMed ID: 9372880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer.
    de Vries SH; Raaijmakers R; Blijenberg BG; Mikolajczyk SD; Rittenhouse HG; Schröder FH
    Urology; 2005 May; 65(5):926-30. PubMed ID: 15882725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
    Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Amirkhan A; Horninger W; Klocker H; Mikolajczyk SD
    J Urol; 2003 Dec; 170(6 Pt 1):2181-5. PubMed ID: 14634374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen.
    Chan TY; Mikolajczyk SD; Lecksell K; Shue MJ; Rittenhouse HG; Partin AW; Epstein JI
    Urology; 2003 Jul; 62(1):177-81. PubMed ID: 12837462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro PSA : a "pro cancer" form of PSA?
    Peyromaure M; Fulla Y; Debré B; Dinh-Xuan AT
    Med Hypotheses; 2005; 64(1):92-5. PubMed ID: 15533620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
    Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
    Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
    Sokoll LJ; Chan DW; Mikolajczyk SD; Rittenhouse HG; Evans CL; Linton HJ; Mangold LA; Mohr P; Bartsch G; Klocker H; Horninger W; Partin AW
    Urology; 2003 Feb; 61(2):274-6. PubMed ID: 12597929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From pro-prostate specific antigen, [-2]pro-prostate specific antigen to Beckman Coulter phi: the evolution of new biomarkers for early detection of prostatic carcinoma.
    Zhang MZ; Lu YP
    Chin Med J (Engl); 2012 May; 125(9):1643-9. PubMed ID: 22800836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
    Michel S; Collomb-Clerc E; Geourjon C; Charrier JP; Passagot J; Courty Y; Deléage G; Jolivet-Reynaud C
    J Mol Recognit; 2005; 18(3):225-35. PubMed ID: 15593306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.